SIGA Stock Recent News

NEW YORK, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against SIGA Technologies, Inc. (“SIGA” or the “Company”) (NASDAQ: SIGA) on behalf of SIGA stockholders. Our investigation concerns whether SIGA has violated the federal securities laws and/or engaged in other unlawful business practices.

SAN FRANCISCO, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Biopharmaceutical company SIGA Technologies is under intense scrutiny over its prior disclosures regarding the potential expansion of its lead product, TPOXX®, to treat Mpox.

NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.

SAN FRANCISCO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Biopharmaceutical company SIGA Technologies is under intense scrutiny over its prior disclosures regarding the potential expansion of its lead product, TPOXX®, to treat Mpox.

Siga Technologies Inc. (SIGA) concluded the recent trading session at $6.96, signifying a +0.58% move from its prior day's close.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of SIGA Technologies, Inc. (“SIGA” or the “Company”) (NASDAQ: SIGA) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your SIGA investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities law.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of SIGA Technologies, Inc. (“SIGA” or the “Company”) (NASDAQ: SIGA) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On September 23, 2024, after market hours, SIGA disclosed that its Chief Medical Officer and Executive Vice President, Dr. Jay Varma, had been terminated from his position.

NEW YORK, NY / ACCESSWIRE / October 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.

NEW YORK, NY / ACCESSWIRE / October 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.

NEW YORK, NY / ACCESSWIRE / September 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.